New leukemia combo aims for higher remission rates
NCT ID NCT07512700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for acute monocytic leukemia, a blood cancer. About 204 people aged 14 to 60 will get either a new drug combo (venetoclax plus CACAG) or standard chemotherapy (3+7). The goal is to see which approach leads to more complete remissions after one cycle.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Air Force Medical Center, PLA
RECRUITINGBeijing, China
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
-
PLA Strategic Support Force's Characteristic Medical Center
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.